The rise of theranostics: Part 2 -- Moving into communities
AuntMinnie
APRIL 4, 2024
Thomas Hope, MD, a radiologist and nuclear medicine physician at the University of California, San Francisco (UCSF), said that approval of lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) radioligand has driven a marked interest and excitement about theranostics and radioligand therapies (RLT). Hope added.
88 
Let's personalize your content